Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Larimar Therapeutics Inc’s stock clocked out at $6.53, up 2.35% from its previous closing price of $6.38. In other words, the price has increased by $2.35 from its previous closing price. On the day, 0.51 million shares were traded. LRMR stock price reached its highest trading level at $6.8 during the session, while it also had its lowest trading level at $6.18.
Ratios:
To gain a deeper understanding of LRMR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.49 and its Current Ratio is at 9.49. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $25.
On November 17, 2023, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.50.
On October 19, 2022, Guggenheim started tracking the stock assigning a Buy rating and target price of $12.Guggenheim initiated its Buy rating on October 19, 2022, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 16 ’24 when Flynn James E bought 4,290,617 shares for $8.74 per share. The transaction valued at 37,499,993 led to the insider holds 6,151,406 shares of the business.
THOMAS FRANK E bought 2,000 shares of LRMR for $22,000 on Feb 14 ’24. The Director now owns 2,000 shares after completing the transaction at $11.00 per share. On Dec 07 ’23, another insider, Shankar Gopi, who serves as the Chief Development Officer of the company, bought 5,000 shares for $3.73 each. As a result, the insider paid 18,662 and bolstered with 5,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LRMR now has a Market Capitalization of 416614016 and an Enterprise Value of 335370112.
Stock Price History:
The Beta on a monthly basis for LRMR is 0.98, which has changed by 0.45111108 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, LRMR has reached a high of $13.68, while it has fallen to a 52-week low of $2.18. The 50-Day Moving Average of the stock is -27.86%, while the 200-Day Moving Average is calculated to be 27.60%.
Shares Statistics:
It appears that LRMR traded 640.99K shares on average per day over the past three months and 362610 shares per day over the past ten days. A total of 43.91M shares are outstanding, with a floating share count of 37.61M. Insiders hold about 41.05% of the company’s shares, while institutions hold 39.02% stake in the company. Shares short for LRMR as of 1711584000 were 3191918 with a Short Ratio of 4.98, compared to 1709164800 on 506814. Therefore, it implies a Short% of Shares Outstanding of 3191918 and a Short% of Float of 6.959999999999999.
Earnings Estimates
At present, 4 analysts are actively evaluating the performance of Larimar Therapeutics Inc (LRMR) in the stock market.On average, analysts expect EPS of -$0.23 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.25, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.25 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.17 and -$1.3 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$2.1, with 3 analysts recommending between -$1.87 and -$2.4.
